Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:15.748Z.
Calculation as of: 2026-10-06T13:25:15.748Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Acurx Pharmaceuticals, Inc.
Market Cap
$5.63M
EV/EBIT Ratio
N/A
Market Cap
$6.03M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.63M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.21M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | N/A |
| Femasys Inc. (FEMY)vs › | $6.10M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
